Biotech Values

[vinmantoo]

ghmm,

I do agree it would have been nice to see some P values, but I am sure the final data will be presented soon. I think you are missing the point a bit in a comparison to NKTR. Relistor has already completed the required one-year safety study, and the PR today is for an oral formulation as opposed to the already approved sub-Q formulation. NKTR is a long way behind as they will need to conduct a one-year safety study. The edge NKTR did have was their drug was an oral formulation, and today's news appears to have removed any NKTR edge.